Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia-Reference-Cited by-同舟云学术

Evaluation of paliperidone palmitate long‐acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia

Published:2019-09-13 Issue:4 Volume:14 Page:428-438
ISSN:1751-7885
Container-title:Early Intervention in Psychiatry
language:en
Short-container-title:Early Intervention in Psychiatry

Author:

Brown Brianne¹^ORCID,Turkoz Ibrahim²,Mancevski Branislav¹,Mathews Maju²

Affiliation:

1. Janssen Scientific Affairs LLC Titusville New Jersey

2. Janssen Research and Development LLC Titusville New Jersey

Funder

Janssen Scientific Affairs, LLC

Publisher

Wiley

Subject

Biological Psychiatry,Psychiatry and Mental health,Pshychiatric Mental Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/eip.12868

Reference35 articles.

2. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent‐onset versus more chronic schizophrenia and a history of criminal justice system involvement;Alphs L.;Early Intervention in Psychiatry,2015

3. Rethinking the role of long‐acting atypical antipsychotics in the community setting;Altamura A. C.;International Clinical Psychopharmacology,2012

4. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

5. Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Long-Term Safety and Tolerability Study of TV-46000 for Subcutaneous Use in Patients with Schizophrenia: A Phase 3, Randomized, Double-Blinded Clinical Trial;CNS Drugs;2024-07-02

2. A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior;Progress in Neuro-Psychopharmacology and Biological Psychiatry;2024-02

3. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria;The Lancet Psychiatry;2023-12

4. The effect of early or late initiation of long-acting antipsychotics on the caregiver burden in schizophrenia;International Clinical Psychopharmacology;2023-11-20

5. Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery;BMC Psychiatry;2023-06-21